Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O.

Lancet. 2017 Jan 6. pii: S0140-6736(16)31403-9. doi: 10.1016/S0140-6736(16)31403-9. [Epub ahead of print]

PMID:
28069279
2.

Exposome-Explorer: a manually-curated database on biomarkers of exposure to dietary and environmental factors.

Neveu V, Moussy A, Rouaix H, Wedekind R, Pon A, Knox C, Wishart DS, Scalbert A.

Nucleic Acids Res. 2017 Jan 4;45(D1):D979-D984. doi: 10.1093/nar/gkw980.

3.

Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report.

Prosvicova J, Lukesova S, Kopecky J, Grim J, Papik Z, Kolarova R, Navratilova B, Dubreuil P, Agopian J, Mansfield C, Moussy A, Hermine O.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Dec;159(4):695-7. doi: 10.5507/bp.2015.061.

4.

Single Cell Dynamics Causes Pareto-Like Effect in Stimulated T Cell Populations.

Cosette J, Moussy A, Onodi F, Auffret-Cariou A, Neildez-Nguyen TM, Paldi A, Stockholm D.

Sci Rep. 2015 Dec 9;5:17756. doi: 10.1038/srep17756.

5.

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.

Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P.

Ann Oncol. 2015 Jun;26(6):1194-200. doi: 10.1093/annonc/mdv133.

6.

Neuroprotective effect of masitinib in rats with postischemic stroke.

Kocic I, Kowianski P, Rusiecka I, Lietzau G, Mansfield C, Moussy A, Hermine O, Dubreuil P.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jan;388(1):79-86. doi: 10.1007/s00210-014-1061-6.

7.

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.

Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A.

Ann Oncol. 2014 Sep;25(9):1762-9. doi: 10.1093/annonc/mdu237.

8.

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.

Vermersch P, Benrabah R, Schmidt N, Zéphir H, Clavelou P, Vongsouthi C, Dubreuil P, Moussy A, Hermine O.

BMC Neurol. 2012 Jun 12;12:36. doi: 10.1186/1471-2377-12-36.

9.

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

Georgin-Lavialle S, Lhermitte L, Suarez F, Yang Y, Letard S, Hanssens K, Feger F, Renand A, Brouze C, Canioni D, Asnafi V, Chandesris MO, Aouba A, Gineste P, Macintyre E, Mansfield CD, Moussy A, Lepelletier Y, Dubreuil P, Hermine O.

Eur J Haematol. 2012 Jul;89(1):47-52. doi: 10.1111/j.1600-0609.2012.01761.x.

PMID:
22324351
10.

Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.

Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, Hermine O.

PLoS One. 2011;6(10):e26375. doi: 10.1371/journal.pone.0026375.

11.

Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.

Cadot P, Hensel P, Bensignor E, Hadjaje C, Marignac G, Beco L, Fontaine J, Jamet JF, Georgescu G, Campbell K, Cannon A, Osborn SC, Messinger L, Gogny-Goubert M, Dubreuil P, Moussy A, Hermine O.

Vet Dermatol. 2011 Dec;22(6):554-64. doi: 10.1111/j.1365-3164.2011.00990.x.

PMID:
21668810
12.

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.

Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, Dubreuil P, Moussy A, Hermine O.

Alzheimers Res Ther. 2011 Apr 19;3(2):16. doi: 10.1186/alzrt75.

13.

Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.

Thamm DH, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, Hermine O, Dubreuil P.

Vet J. 2012 Jan;191(1):131-4. doi: 10.1016/j.tvjl.2011.01.001.

PMID:
21333567
14.

Safety of masitinib mesylate in healthy cats.

Daly M, Sheppard S, Cohen N, Nabity M, Moussy A, Hermine O, Wilson H.

J Vet Intern Med. 2011 Mar-Apr;25(2):297-302. doi: 10.1111/j.1939-1676.2011.0687.x.

15.

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.

Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmérini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O.

Am J Hematol. 2010 Dec;85(12):921-5. doi: 10.1002/ajh.21894.

16.

Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.

Hahn KA, Legendre AM, Shaw NG, Phillips B, Ogilvie GK, Prescott DM, Atwater SW, Carreras JK, Lana SE, Ladue T, Rusk A, Kinet JP, Dubreuil P, Moussy A, Hermine O.

Am J Vet Res. 2010 Nov;71(11):1354-61. doi: 10.2460/ajvr.71.11.1354. Erratum in: Am J Vet Res. 2011 Feb;72(2):247.

PMID:
21034327
17.

Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.

Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, Moussy A, Kinet JP, Hermine O, Rougier P, Raymond E.

Cancer Chemother Pharmacol. 2010 Jul;66(2):395-403. doi: 10.1007/s00280-010-1299-8.

PMID:
20364428
18.

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O.

Eur J Cancer. 2010 May;46(8):1344-51. doi: 10.1016/j.ejca.2010.02.014.

PMID:
20211560
19.

Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.

Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A, Hermine O, Dubreuil P.

PLoS One. 2010 Mar 4;5(3):e9430. doi: 10.1371/journal.pone.0009430.

20.

Drug-induced minimal change nephropathy in a dog.

Sum SO, Hensel P, Rios L, Brown S, Howerth EW, Driskell EA, Moussy A, Hermine O, Brown CA.

J Vet Intern Med. 2010 Mar-Apr;24(2):431-5. doi: 10.1111/j.1939-1676.2010.0471.x. No abstract available.

Items per page

Supplemental Content

Loading ...
Support Center